home / stock / eras / eras news

ERAS News and Press, Erasca Inc. From 05/08/24

Stock Information
Company Name: Erasca Inc.
Stock Symbol: ERAS
Market: NASDAQ
Website: erasca.com
Menu
ERAS ERAS Quote ERAS Short ERAS News ERAS Articles ERAS Message Board
Get ERAS Alerts

News, Short Squeeze, Breakout and More Instantly...
ERAS - Erasca Reports First Quarter 2024 Business Updates and Financial Results

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketab...
ERAS - Erasca to Present at the Bank of America Health Care Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank o...

ERAS - Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and p...

ERAS - Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

2024-03-29 11:11:07 ET Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Conference Call March 28, 2024, 08:30 ET Company Participants Jonathan Lim - Chairman, CEO & Co-founder Shannon Morris - Chief Medical Officer David Chacko - CFO & Chief B...
ERAS - Erasca to get $45M funding via private placement

2024-03-28 03:56:41 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca Read the full article on Seeking Alpha For further details see: Erasca to get $45M funding via...

ERAS - Erasca Announces $45 Million Oversubscribed Private Placement Financing

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it h...

ERAS - Erasca GAAP EPS of -$0.20

2024-03-27 16:41:57 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca Read the full article on Seeking Alpha For further details see: Erasca GAAP EPS of -$0.20
ERAS - Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal ...

ERAS - Big Pharma patent cliffs seen fueling oncology M&A this year

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

ERAS - Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected ...
Previous 10 Next 10